Journal article
CaMKII-based gene therapy protects retinal ganglion cells in a broad range of disease: ischemic retinopathy and congenital glaucoma
Molecular therapy
02/02/2026
DOI: 10.1016/j.ymthe.2026.01.036
PMID: 41635083
Abstract
Degeneration of retinal ganglion cells (RGCs) and their axons, as observed in ischemic retinopathy and glaucoma, results in irreversible vision loss. Elevated intraocular pressure (IOP) is a key factor driving these conditions, with existing treatments focused on IOP reduction often proving inadequate to halt disease progression. Here, we report that CaMKII-based gene therapy robustly protects RGCs and preserves visual function in mouse models of ischemic injury and congenital glaucoma, positioning CaMKII as a broad therapeutic target for retinal diseases driven by acute and chronic IOP elevation that damage RGCs.
Details
- Title: Subtitle
- CaMKII-based gene therapy protects retinal ganglion cells in a broad range of disease: ischemic retinopathy and congenital glaucoma
- Creators
- Jing Zhou - Sichuan UniversityYue Wan - Chinese Academy of Medical Sciences & Peking Union Medical CollegeMichael G Anderson - University of IowaElia J Duh - Johns Hopkins MedicineJonathan B Demb - Yale UniversityXinzheng Guo - Chinese Academy of Medical Sciences & Peking Union Medical CollegeBo Chen - Mount Sinai Hospital
- Resource Type
- Journal article
- Publication Details
- Molecular therapy
- DOI
- 10.1016/j.ymthe.2026.01.036
- PMID
- 41635083
- NLM abbreviation
- Mol Ther
- ISSN
- 1525-0016
- eISSN
- 1525-0024
- Publisher
- Elsevier
- Language
- English
- Electronic publication date
- 02/02/2026
- Academic Unit
- Molecular Physiology and Biophysics; Ophthalmology and Visual Sciences
- Record Identifier
- 9985139318402771
Metrics
1 Record Views